



WAVEPulse™ Sterilization technology

WAVEPulse™ Sterilization technology fragments proteins, providing a high level of sterilization, disinfection, and deimmunization of organisms that frequently cause hospital-acquired infections and at temperatures that are compatible with heat-sensitive instruments.

Challenges in sterilizing medical devices

- Limited efficacy of low-temperature disinfection processes
- Failure to achieve sterilization due to residual pathogens and limited effectiveness of current methods
- No effective methods to destroy stable proteins (e.g., prions)
- Liability risk on the part of healthcare providers and equipment suppliers


Protein destruction delivers sterilization

- Successful sterilization tests in lumens and elevator mechanism of a duodenoscope
- Uses two continuously non-toxic and non-corrosive aqueous solvents to achieve sterilization at approximately 60 °C in less than a 1-hour cycle
- Durability tests for endoscopes undergoing **WAVEPulse™ Sterilization** process
- US and foreign patent-pending technology - combines microwave, heat and non-toxic solvents
- Repeated, consistent and superior bench testing results
- 10⁻¹⁰ Sterility Assurance Level (SAL)
- Anthrax surrogate sterilization (spore of greatest resistance)
- Prion destruction

WAVEPulse™ Sterilization addresses the common problems of equipment cross-contamination and incomplete disinfection that contribute to approximately 100,000 U.S. based HAI-related deaths annually.

Application areas

- Automatic Endoscope Reprocessing
- Surgical instrument sterilization
- Surgical system sterilization
- Reprocessing of single-use devices



ONEighty C Technologies Corporation

70 Blanchard Road, Burlington, MA, USA 01803

<http://www.oneightyc.com>

eric.walters@oneightyc.com

Founded in 2013

Delaware C Corp, registered in Massachusetts

Mission

Develop market leadership by offering advanced solutions that set new standards for high-performance medical instrument sterilization and validation

Leadership

Eric G. Walters, Co-Founder & CEO

Michael G. Fritz, Board of Directors

Theresa O'Keefe, Ph.D., Scientific Development

Michael Druess, Ph.D., Regulatory Strategy